Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Multicenter Real-World Experience
DPd and DKd demonstrated similar clinical efficacies in RRMM patients, although their toxicity profiles differed. These findings highlight the importance of individualized treatment decisions considering underlying patient comorbidities and prior drug exposure. These findings support the use of either regimen in appropriate patient subsets, based on efficacy and distinct safety profiles.
Authors
- Gray Magee (ORCID: https://orcid.org/0009-0008-2105-2228)
- Zahra Mahmoudjafari (ORCID: https://orcid.org/0000-0002-3168-2521)
- Jeries Kort (ORCID: https://orcid.org/0000-0001-9182-3931)
- Al-Ola A. Abdallah (ORCID: https://orcid.org/0000-0002-6603-185X)
- Muhammad Umair Mushtaq (ORCID: https://orcid.org/0000-0001-8122-0563)
- Shebli Atrash (ORCID: https://orcid.org/0000-0003-4547-7534)
- Razan Mansour (ORCID: https://orcid.org/0000-0002-7719-9068)
- Mark Chang (ORCID: https://orcid.org/0000-0002-7029-0985)
- Barry Paul (ORCID: https://orcid.org/0000-0003-2702-8225)
- Kimberly M Green (ORCID: https://orcid.org/0009-0003-1150-5506)
- James A. Davis (ORCID: https://orcid.org/0000-0001-7978-1652)
- Nausheen Ahmed (ORCID: https://orcid.org/0000-0003-4336-4982)
- Anas Zayad (ORCID: https://orcid.org/0009-0006-7537-0112)
- Barry Skikne
Institutions
- Medical University of South Carolina (US)
- Levine Cancer Institute (US)
- University of Kansas Medical Center (US)
- Cellular Therapeutics (United Kingdom) (GB)
- Hamad Medical Corporation (QA)
Publication Details
- Journal
- Clinical Lymphoma Myeloma & Leukemia
- Published
- 2025-08-27
- DOI
- https://doi.org/10.1016/j.clml.2025.08.017
- Citations
- 2
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.54